Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 8
  • 3
  • 13
  • 26
  • 9
  • 3
  • 23

Found 26 Lancaster General Health trials

A listing of Lancaster General Health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World (DISCOVER-HCM)
18-99 years
All genders
Phase 4
The purpose of this registry is to understand the safety and effectiveness of various medications used in treating the condition of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a type of heart disease that causes the muscular wall in the chambers of the heart to thicken which can cause blood flow in …
 Parasympathetic Augmentation via Respiratory Training for Patients with Systolic Heart Failure
18-99 years
All genders
Phase 4
The purpose of this study is to evaluate the effect of breath training on patients with systolic heart failure. The study evaluates patients and incorporates the use of smart phone technology for breath training at baseline and at three and six months, using the 6-minute walk test, a standard heart …
 Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
18-99 years
All genders
The purpose of this study is to evaluate if closing off the left atrial appendage (LAA) of your heart (a small-sack like structure that is part of the upper chamber of the heart) during scheduled heart surgery with a surgical device known as the AtriClip, reduces the risk of a …
 MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC
18-100 years
All genders
Phase 3
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is …
 A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)
18 years and older
Female
Phase 2
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability  of luveltamab tazevibulin in …
 BOLT
99 years and younger
All genders
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
 ACCLAIM-Lp(a) EZEF
99 years and younger
All genders
Phase 3
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular (CV) risk in participants with high lipoprotein(a) who have CV disease or are at risk of a heart attack or stroke. The study aims to learn whether lepodisiran can reduce problems like heart attack or …
 TRIUMPH-OUTCOMES
99 years and younger
All genders
Phase 3
The main purpose of this study is to learn more about retatrutide, an investigational treatment for participants with BMI of greater than or equal to 27 kg/m2 (kilogram per square meter) and heart related and/or kidney related disease. About 10,000 participants will be randomized to receive either retatrutide or placebo …
 Left vs Left RCT
99 years and younger
All genders
This study aims to test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications. This is for patients with heart failure who are already receiving current …
 CARDIO-TTRansform OLE
99 years and younger
All genders
This is a multicenter, open-label extension of the ION-682884-CS2 Study (CARDIO-TTRansform) and of the ISIS 420915-CS101 Study. Eligible participants will receive eplontersen once every 4 weeks for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first. Participants will also …
1 - 10 of 26